Nearly two years after clinical setbacks cratered Q32’s stock price, new results showed hair growth improvements that surpassed investors’ expectations.
An article from
Dive Brief
Nearly two years after clinical setbacks cratered Q32’s stock price, new results showed hair growth improvements that surpassed investors’ expectations.
Published July 13, 2026
Shares of Q32 Bio surged more than 80% on July 13, 2026.
Q32 Bio Stock Soars After Patchy Hair Loss Study - Here's Why - Q32 Bio (NASDAQ:QTTB)
Q32 Bio Announces Positive 36-Week Topline Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata
Q32 Bio to Report 36-Week Topline Results from Part B of SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata on July 13, 2026
Veradermics declares first efficacy win in women for hair loss drug
Why Is Q32 Bio Stock Falling Wednesday? - Q32 Bio (NASDAQ:QTTB)
Why Is Biogen Stock Falling Tuesday? - Biogen (NASDAQ:BIIB)
Pharmalittle: We're reading about a Biogen Alzheimer's drug, skyrocketing 340B drug sales, and more
Q32 Bio reported positive Phase 2a data for bempikibart in severe alopecia areata, showing hair regrowth and favorable safety.
Q32 Bio Announces Positive 36-Week Topline Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata
Q32 Bio to Report 36-Week Topline Results from Part B of SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata on July 13,…
Q32 Bio Announces $55 Million Private Placement Financing
Q32 Bio ($QTTB) jumps in premarket trading after securing a $55M private placement to fund its autoimmune pipeline. Read more.
The Phase 2 data exceeded expectations, lifting company shares as high as nearly $130 apiece and building the case for what may…
